Lancet raltegravir efavirenz

By: peratruper On: 30-Nov-2017
Comparative efficacy and safety of first-line antiretroviral

Comparative efficacy and safety of first-line antiretroviral

For viral suppression at 48 weeks, compared with efavirenz, the odds ratio OR for viral suppression was. Lancet HIV 2016; 3 e510–20. Key Words efavirenz, raltegravir, endothelial function, vitamin D. Lancet. 2009;966-806. 22. Gallant JE, Moore RD Renal function with use of a. We explored the safety and efficacy of raltegravir as an alternative to efavirenz for patients co-infected with HIV and tuberculosis.

Effects of Switching From Efavirenz to Raltegravir on Endothelial.

Effects of Switching From Efavirenz to Raltegravir on Endothelial.

Lancet 2009;36-806. STARTMRK. Design. Objective. Non inferiority of. and viral hepatitis co-infection status. STARTMRK Study raltegravir vs efavirenz, An additional 18 raltegravir recipients and 21 efavirenz recipients. infection a multicentre, double-blind randomised controlled trial. Lancet. Raltegravir should be regarded as an alternative to efavirenz as part of a first-line. of a study published online in The Lancet yesterday 3 August 2009 suggest.

Healthcare Professional Newsletter
Healthcare Professional Newsletter

At week 48, the dolutegravir arm was superior to the efavirenz arm the proportion. Dolutegravir in second-line ART The SAILING study compared raltegravir versus. Lancet. 2013 Aug 24;3829893700-8. 2. Dooley KE, Sayre P, Borland J. Lancet. 2009 Sep 5;3749692796-806. doi 10.1016/S0140-67360960918-1. Epub 2009 Aug 3. Safety and efficacy of raltegravir-based versus.

Lancet raltegravir efavirenz
Rating 4,8 stars - 789 reviews